Skip to main content
SpringerLink
Log in

Impact of Alpha-Radiotherapy on the Tumor Microenvironment

  • Living reference work entry
  • First Online:
Handbook of Cancer and Immunology

  • 79 Accesses

Abstract

Alpha-radiotherapy is an internal radiation therapy based on the use of α-particle emitters. These radionuclides are highly cytotoxic and altogether their characteristics make them of particular interest in the treatment of disseminated cancers, minimal residual disease, and micro-metastases. Nowadays there is a growing interest for these α-emitters whose development in the clinic was so far limited. Indeed remarkable clinical results have been observed in hematological malignancies and lately in metastatic castration-resistant prostate cancer.

Apart from their direct cytotoxic potential on tumor cells, studies have also investigated the bystander effects of alpha-radiotherapy, in particular on the tumor microenvironment including the vascular and the immune components. Depending on the type of tumor and on the α-radionuclide, the scope of these studies could help specify the optimal conditions for the use of alpha-radiotherapy as well as the combination therapies most likely to potentiate tumor eradication.

In this chapter we review and discuss the preclinical in vitro and in vivo studies that have analyzed the impact of α-particle emitters on the tumor microenvironment as well as the few combination therapies that have been reported so far.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  • Alam M, Nanda S, Mittal BB, Kim NA, Yoo S (2011) The use of brachytherapy in the treatment of nonmelanoma skin cancer: a review. J Am Acad Dermatol 65(2):377–388

    Article  PubMed  Google Scholar 

  • Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P et al (2005) Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 4(12):1318–1324

    Article  PubMed  CAS  Google Scholar 

  • Allen BJ, Singla AA, Rizvi SMA, Graham P, Bruchertseifer F, Apostolidis C et al (2011) Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy 3(9):1041–1050

    Article  PubMed  CAS  Google Scholar 

  • Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J et al (2009) Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab’)2 – a phase I study. J Nucl Med 50(7):1153–1160

    Article  PubMed  CAS  Google Scholar 

  • Atallah E, Berger M, Jurcic J, Roboz G, Tse W, Mawad R et al (2019) A phase 2 study of Actinium-225 (225Ac)-lintuzumab in older patients with untreated Acute Myeloid Leukemia (AML). J Med Imaging Radiat Sci 50(1):S37

    Article  Google Scholar 

  • Bauman G, Charette M, Reid R, Sathya J (2005) Care TRGG of CCOP in E. Radiopharmaceuticals for the palliation of painful bone metastases – a systematic review. Radiother Oncol 75(3):258.E1–258.E13

    Article  Google Scholar 

  • Behling K, Maguire WF, Gialleonardo VD, Heeb LEM, Hassan IF, Veach DR et al (2016a) Remodeling the vascular microenvironment of glioblastoma with α-particles. J Nucl Med 57(11):1771–1777

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Behling K, Maguire WF, Puebla JCL, Sprinkle SR, Ruggiero A, O’Donoghue J et al (2016b) Vascular targeted radioimmunotherapy for the treatment of glioblastoma. J Nucl Med 57(10):1576–1582

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW et al (2003) Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101(12):5068–5075

    Article  PubMed  CAS  Google Scholar 

  • Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW et al (2004) Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 78(3):352–359

    Article  PubMed  CAS  Google Scholar 

  • Bicak M, Lückerath K, Kalidindi T, Phelps ME, Strand S-E, Morris MJ et al (2020) Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proc Natl Acad Sci U S A 117(26):15172–15181

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chatal J-F, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez J-P, Charbonnel B et al (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24(11):1705–1711

    Article  PubMed  CAS  Google Scholar 

  • Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS et al (2012) Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood 119(5):1130–1138

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Corroyer-Dulmont A, Valable S, Falzone N, Frelin-Labalme A-M, Tietz O, Toutain J et al (2020) VCAM-1 targeted alpha-particle therapy for early brain metastases. Neuro-Oncology 22(3):357–368

    Article  PubMed  CAS  Google Scholar 

  • D’Andrea AD (2018) Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71:172–176

    Article  PubMed  Google Scholar 

  • Dabagian H, Taghvaee T, Martorano P, Martinez D, Samanta M, Watkins CM et al (2021) PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma. ACS Pharmacol Transl Sci 4(1):344–351

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dekempeneer Y, Caveliers V, Ooms M, Maertens D, Gysemans M, Lahoutte T et al (2020) Therapeutic efficacy of 213Bi-labeled sdAbs in a preclinical model of ovarian cancer. Mol Pharma 17(9):3553–3566

    Article  CAS  Google Scholar 

  • Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C et al (2021) Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of Lutetium-177-PSMA. Eur Urol 79(3):343–350

    Article  PubMed  CAS  Google Scholar 

  • Foray N (2016) Victor Despeignes, the forgotten pioneer of radiation oncology. Int J Radiat Oncol Biol Phys 96(4):717–721

    Article  PubMed  Google Scholar 

  • Goldsmith SJ (2020) Targeted radionuclide therapy: a historical and personal review. Semin Nucl Med 50(1):87–97

    Article  PubMed  Google Scholar 

  • Gorin J-B, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A et al (2014) Antitumor immunity induced after α irradiation. Neoplasia 16(4):319–328

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Gupta N, Devgan A, Bansal I, Olsavsky TD, Li S, Abdelbaki A et al (2018) Usefulness of Radium-223 in patients with bone metastases. Proc (Bayl Univ Med Cent) 30(4):424–426

    Google Scholar 

  • Hallqvist A, Bergmark K, Bäck T, Andersson H, Dahm-Kähler P, Johansson M et al (2019) Intraperitoneal α-emitting radioimmunotherapy with 211At in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations. J Nucl Med 60(8):1073–1079

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S et al (2019) Preclinical efficacy of a PSMA-targeted Thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer. Clin Cancer Res 26(8):1985–1996

    Google Scholar 

  • Hammer S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, Hagemann UB, Scholz A et al (2021) Darolutamide potentiates the antitumor efficacy of a PSMA-targeted Thorium-227 conjugate by a dual mode of action in prostate cancer models. Clin Cancer Res 27(15):4367–4378

    Article  PubMed  CAS  Google Scholar 

  • Hepel JT, Wazer DE (2012) A comparison of brachytherapy techniques for partial breast irradiation. Brachytherapy 11(3):163–175

    Article  PubMed  Google Scholar 

  • Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T et al (2018) [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19(6):825–833

    Article  PubMed  CAS  Google Scholar 

  • Hohloch K, Delaloye AB, Windemuth-Kieselbach C, Gómez-Codina J, Linkesch W, Jurczak W et al (2011) Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunotherapy network. J Nucl Med 52(9):1354–1360

    Article  PubMed  Google Scholar 

  • Jiao R, Allen KJH, Malo ME, Rickles D, Dadachova E (2020) Evaluating the combination of radioimmunotherapy and immunotherapy in a melanoma mouse model. Int J Mol Sci 21(3):773

    Article  PubMed Central  CAS  Google Scholar 

  • Jurcic JG (2018) Clinical studies with Bismuth-213 and Actinium-225 for hematologic malignancies. Curr Radiopharm 11(3):192–199

    Article  PubMed  CAS  Google Scholar 

  • Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR et al (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100(4):1233–1239

    Article  PubMed  CAS  Google Scholar 

  • Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441–449

    Article  PubMed  CAS  Google Scholar 

  • Kassis AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Sem Nucl Med 38(5):358–366

    Article  Google Scholar 

  • Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM (2007) Radioimmunotherapy with α-particle–emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 13(18):5604s–5612s

    Article  PubMed  CAS  Google Scholar 

  • Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP (2018) Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with Lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm 33(7):274–281

    Article  PubMed  CAS  Google Scholar 

  • Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H et al (2020) 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 47(3):721–728

    Article  PubMed  CAS  Google Scholar 

  • Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E et al (2014) Radioimmunoconjugates for the treatment of cancer. Semin Oncol 41(5):613–622

    Article  PubMed  Google Scholar 

  • Kratochwil C, Giesel FL, Bruchertseifer F, Mier W, Apostolidis C, Boll R et al (2014) 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging 41(11):2106–2119

    Google Scholar 

  • Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W et al (2017) Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med 58(10):1624–1631

    Article  PubMed  CAS  Google Scholar 

  • Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U et al (2018) Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med 59(5):795–802

    Article  PubMed  CAS  Google Scholar 

  • Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Fur PL et al (2019) Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and nontargeted response to alpha and auger radioimmunotherapy. Clin Cancer Res 25(15):4775–4790

    Article  PubMed  CAS  Google Scholar 

  • Langley S, Ahmed HU, Al-Qaisieh B, Bostwick D, Dickinson L, Veiga FG et al (2012) Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 109(s1):7–16

    Article  PubMed  Google Scholar 

  • Lejeune P, Cruciani V, Berg-Larsen A, Schlicker A, Mobergslien A, Bartnitzky L et al (2021) Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy. J Immunother Cancer 9(10):e002387

    Article  PubMed  PubMed Central  Google Scholar 

  • Li HK, Morokoshi Y, Nagatsu K, Kamada T, Hasegawa S (2017) Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. Cancer Sci 108(8):1648–1656

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Malamas AS, Gameiro SR, Knudson KM, Hodge JW (2016) Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget 7(52):86937–86947

    Article  PubMed  PubMed Central  Google Scholar 

  • Malo ME, Allen KJH, Jiao R, Frank C, Rickles D, Dadachova E (2020) Mechanistic insights into synergy between melanin-targeting radioimmunotherapy and immunotherapy in experimental melanoma. Int J Mol Sci 21(22):8721

    Article  PubMed Central  CAS  Google Scholar 

  • Marotte L, Capitao M, Deleine C, Beauvais T, Cadiou G, Perrin J et al (2021) Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes. Onco Targets Ther 10(1):1940676

    CAS  Google Scholar 

  • Maserumule LC, Mokoala KMG, Hlongwa KN, Ndlovu H, Reed JD, Ismail A et al (2021) Exceptional initial response of prostate cancer lung metastases to 225Ac-PSMA: A case report. Curr Probl Cancer Case Rep 3:100038

    Google Scholar 

  • Ménager J, Gorin J-B, Maurel C, Drujont L, Gouard S, Louvet C et al (2015) Combining α-radioimmunotherapy and adoptive T cell therapy to potentiate tumor destruction. PLoS One 10(6):e0130249

    Article  PubMed  PubMed Central  Google Scholar 

  • Meredith R, Torgue J, Shen S, Fisher DR, Banaga E, Bunch P et al (2014) Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-Trastuzumab. J Nucl Med 55(10):1636–1642

    Article  PubMed  CAS  Google Scholar 

  • Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD et al (2018) Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 41(7):716–721

    Article  PubMed  CAS  Google Scholar 

  • Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J et al (2007) Potentiation of high-LET radiation by Gemcitabine: targeting HER2 with Trastuzumab to treat disseminated peritoneal disease. Clin Cancer Res 13(6):1926–1935

    Article  PubMed  CAS  Google Scholar 

  • Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ et al (2008) Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease. Clin Cancer Res 14(16):5108–5115

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW (2013) Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation. Cancer Biother Radiopharm 28(6):441–449

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Milenic DE, Baidoo KE, Kim Y-S, Brechbiel MW (2015) Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. MAbs 7(1):255–264

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Nosanchuk JD, Jeyakumar A, Ray A, Revskaya E, Jiang Z, Bryan RA et al (2018) Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Sci Rep 8(1):5466

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ohshima Y, Sudo H, Watanabe S, Nagatsu K, Tsuji AB, Sakashita T et al (2018) Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model. Eur J Nucl Med Mol Imaging 45(6):999–1010

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pelletier K, Côté G, Fallah-Rad N, John R, Kitchlu A (2020) CKD after 225Ac-PSMA617 therapy in patients with metastatic prostate cancer. Kidney Int Rep 6(3):853–856

    Article  PubMed  PubMed Central  Google Scholar 

  • Perrin J, Capitao M, Allard M, Chouin N, Gouard S, Marionneau-Lambot S et al (2021) Targeted alpha particle therapy remodels the tumor microenvironment and improves efficacy of immunotherapy. Int J Radiat Oncol Biol Phys S0360-3016(21):02919–02919

    Google Scholar 

  • Raja C, Graham P, Rizvi SMA, Song E, Goldsmith H, Thompson J et al (2007) Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 6(6):846–852

    Article  PubMed  CAS  Google Scholar 

  • Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C et al (2021) First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT. Eur J Nucl Med Mol Imaging 48(1):311–312

    Article  PubMed  Google Scholar 

  • Robbins RJ, Schlumberger MJ (2005) The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S–37S

    PubMed  CAS  Google Scholar 

  • Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J et al (2021a) Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics. 11(9):4050–4060

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I et al (2021b) Efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 radioligand therapy in patients with highly advanced mCRPC with poor prognosis. Pharmaceutics 13(5):722

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS et al (2010) Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 16(21):5303–5311

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Salaun P-Y, Campion L, Bournaud C, Faivre-Chauvet A, Vuillez J-P, Taieb D et al (2012) Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement. J Nucl Med 53(8):1185–1192

    Article  PubMed  CAS  Google Scholar 

  • Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW et al (2002) Bismuth 213–labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 100(1):318–326

    Article  PubMed  CAS  Google Scholar 

  • Satapathy S, Mittal BR, Sood A, Das CK, Singh SK, Mavuduru RS et al (2020) Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. Indian J Nucl Med 35(4):299–304

    Article  PubMed  PubMed Central  Google Scholar 

  • Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T et al (2019a) 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46(1):129–138

    Article  PubMed  CAS  Google Scholar 

  • Sathekge MM, Bruchertseifer F, Lawal IO, Vorster M, Knoesen O, Lengana T et al (2019b) Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617. Eur J Nucl Med Mol Imaging 46(8):1756–1757

    Article  PubMed  Google Scholar 

  • Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J et al (2020) Predictors of overall and disease free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med 61(1):62–69

    Article  PubMed  CAS  Google Scholar 

  • Sattiraju A, Xiong X, Pandya DN, Wadas TJ, Xuan A, Sun Y et al (2017) Alpha particle enhanced blood brain/tumor barrier permeabilization in glioblastomas using integrin alpha-v beta-3–targeted liposomes. Mol Cancer Ther 16(10):2191–2200

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Saung MT, Zheng L (2017) Current standards of chemotherapy for pancreatic cancer. Clin Ther 39(11):2125–2134

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Brill AB et al (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51(2):311–328

    Article  PubMed  CAS  Google Scholar 

  • Stewart AJ, Viswanathan AN (2006) Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer 107(5):908–915

    Article  PubMed  Google Scholar 

  • Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 trial of 177Lu-dotatate for Midgut neuroendocrine tumors. N Engl J Med 376(2):125–135

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sudo H, Tsuji AB, Sugyo A, Kaneko MK, Kato Y, Nagatsu K et al (2021) Preclinical evaluation of podoplanin-targeted alpha-radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma. Cells 10(10):2503

    Google Scholar 

  • Supiot S, Thillays F, Rio E, Gouard S, Morgenstern A, Bruchertseifer F et al (2007) Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation. Radiother Oncol 83(1):97–101

    Article  PubMed  CAS  Google Scholar 

  • Urbanska AM, Khanin R, Alidori S, Wong S, Mello BP, Almeida BA et al (2020) A genomic profile of local immunity in the melanoma microenvironment following treatment with α particle-emitting ultrasmall silica nanoparticles. Cancer Biother Radiopharm 35(6):459–473

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Veirman KD, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E et al (2021) CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in multiple myeloma. Onco Targets Ther 10(1):2000699

    Google Scholar 

  • Weaver BA (2014) How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 25(18):2677–2681

    Article  PubMed  PubMed Central  Google Scholar 

  • Weber AM, Ryan AJ (2015) ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 149:124–138

    Article  PubMed  CAS  Google Scholar 

  • Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H et al (2019) Preclinical combination studies of an FGFR2 targeted Thorium-227 conjugate and the ATR inhibitor BAY 1895344. Int J Radiat Oncol Biol Phys 105(2):410–422

    Article  PubMed  CAS  Google Scholar 

  • Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463

    Article  PubMed  CAS  Google Scholar 

  • Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C (2020) Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics 10(20):9364–9377

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW (2013a) Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int J Radiat Oncol Biol Phys 85(4):1119–1126

    Article  PubMed  CAS  Google Scholar 

  • Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW (2013b) 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint. Br J Cancer 108(10):2013–2020

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49(1):30–38

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nantes Université, Inserm, CNRS, Université d’Angers, CRCI2NA, Nantes, France

    Mathilde Allard, Justine Perrin, Yannick Guilloux, Françoise Kraeber-Bodéré, Michel Chérel & Joëlle Gaschet

  2. LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France

    Mathilde Allard, Justine Perrin, Yannick Guilloux & Joëlle Gaschet

  3. Department of Nuclear Medicine, University Hospital of Nantes, Nantes, France

    Françoise Kraeber-Bodéré

  4. LabEx IRON “Innovative Radiopharmaceuticals in Oncology and Neurology”, Nantes, France

    Françoise Kraeber-Bodéré & Michel Chérel

  5. Institut de Cancérologie de l’Ouest, Saint Herblain, France

    Michel Chérel

  6. GIP Arronax, Saint Herblain, France

    Michel Chérel

Authors
  1. Mathilde Allard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Justine Perrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yannick Guilloux
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Françoise Kraeber-Bodéré
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michel Chérel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joëlle Gaschet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joëlle Gaschet .

Editor information

Editors and Affiliations

  1. Division of Clinical Immunology, Karolinska University Hospital, Huddinge, Sweden

    Nima Rezaei

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Allard, M., Perrin, J., Guilloux, Y., Kraeber-Bodéré, F., Chérel, M., Gaschet, J. (2022). Impact of Alpha-Radiotherapy on the Tumor Microenvironment. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_116-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-80962-1_116-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-80962-1

  • Online ISBN: 978-3-030-80962-1

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation